logo-loader
viewAstraZeneca

FDA grants “priority review” status to AstraZeneca’s breast cancer antibody

“Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer"

AstraZeneca - US authority grants “priority review” status to AstraZeneca’s breast cancer antibody
Rastuzumab deruxtecan is an antibody drug conjugate targeting HER2, a protein found on the surface of some cancer cells in breast cancer patients

Pharma company AstraZeneca PLC (LON:AZN) has announced the US Food and Drug Administration (FDA) granted “priority review” status to its breast cancer antibody.

Rastuzumab deruxtecan is an antibody drug conjugate targeting HER2, a protein found on the surface of some cancer cells in breast cancer patients, and is a potential new medicine to treat metastatic breast cancer.

READ: AstraZeneca gets US clearance for asthma pen

“Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today,” said José Baselga, executive vice president for oncology research and development.

“This priority review draws on the strength and the consistency of results seen in the Phase I and Phase II trials and is a critical step on the journey to deliver this potential new medicine to patients.”

Quick facts: AstraZeneca

Price: 7257 GBX

LSE:AZN
Market: LSE
Market Cap: £95.3 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks reel after Canopy Growth posts eye-popping...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada dropped 5.6% at 114.9 points. Elsewhere, the OTCQX Cannabis Index sank 4.2% at 430.2 points. Duds today were Canopy Growth Corp (TSE:WEED) (NYSE:CGC), Aurora Cannabis Inc (TSE:ACB)...

14 hours, 35 minutes ago

2 min read